Aeed, P. A., Young, C. L., Nagiec, M. M. and Elhammer, A. P. (2009). Inhibition of inositol phosphorylceramide synthase by the cyclic peptide Aureobasidin A. Antimicrobial Agents and Chemotherapy
53, 496–504.
Antczak, M., Dzitko, K. and Dlugonska, H. (2016). Human toxoplasmosis-Searching for novel chemotherapeutics. Biomedicine and Pharmacotherapy
82, 677–684.
Azzouz, N., Rauscher, B., Gerold, P., Cesbron-Delauw, M. F., Dubremetz, J. F. and Schwarz, R. T. (2002). Evidence for de novo sphingolipid biosynthesis in Toxoplasma gondii
. International Journal for Parasitology
32, 677–684.
Cerantola, V., Guillas, I., Roubaty, C., Vionnet, C., Uldry, D., Knudsen, J. and Conzelmann, A. (2009). Aureobasidin A arrests growth of yeast cells through both ceramide intoxication and deprivation of essential inositolphosphorylceramides. Molecular Microbiology
71, 1523–1537.
Chowdhury, M. N. (1986). Toxoplasmosis: a review. Journal of Medicine
17, 373–396.
Coppens, I. (2013). Targeting lipid biosynthesis and salvage in apicomplexan parasites for improved chemotherapies. Nature Reviews Microbiology
11, 823–835.
Denny, P. W., Shams-Eldin, H., Price, H. P., Smith, D. F. and Schwarz, R. T. (2006). The protozoan inositol phosphorylceramide synthase: a novel drug target which defines a new class of sphingolipid synthase. Journal of Biological Chemistry
281, 28200–28209.
Dubey, J. P. (1977).
Toxoplasma, Hammondia, Besnotia, Sarcocystis, and other cyst-forming coccidia of man and animals. In Parasitic Protozoa (ed. Kreier, J. P.), pp. 101–237. Academic Press, New York.
Figueiredo, J. M., Dias, W. B., Mendonca-Previato, L., Previato, J. O. and Heise, N. (2005). Characterization of the inositol phosphorylceramide synthase activity from Trypanosoma cruzi
. Biochemical Journal
387, 519–529.
Georgopapadakou, N. H. (2000). Antifungals targeted to sphingolipid synthesis: focus on inositol phosphorylceramide synthase. Expert Opinions on Investigative Drugs
9, 1787–1796.
Gerold, P. and Schwarz, R. T. (2001). Biosynthesis of glycosphingolipids de-novo by the human malaria parasite Plasmodium falciparum
. Molecular and Biochemical Parasitology
112, 29–37.
Gubbels, M. J., Li, C. and Striepen, B. (2003). High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein. Antimicrobial Agents and Chemotherapy
47, 309–316.
Hanada, K. (2005). Sphingolipids in infectious diseases. Japanese Journal of Infectious Diseases
58, 131–148.
Hanada, K., Nishijima, M., Kiso, M., Hasegawa, A., Fujita, S., Ogawa, T. and Akamatsu, Y. (1992). Sphingolipids are essential for the growth of Chinese hamster ovary cells. Restoration of the growth of a mutant defective in sphingoid base biosynthesis by exogenous sphingolipids. Journal of Biological Chemistry
267, 23527–23533.
Heidler, S. A. and Radding, J. A. (1995). The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent Aureobasidin A (LY295337). Antimicrobial Agents and Chemotherapy
39, 2765–2769.
Huitema, K., Van Den Dikkenberg, J., Brouwers, J. F. and Holthuis, J. C. (2004). Identification of a family of animal sphingomyelin synthases. EMBO Journal
23, 33–44.
Ikai, K., Takesako, K., Shiomi, K., Moriguchi, M., Umeda, Y., Yamamoto, J., Kato, I. and Naganawa, H. (1991). Structure of Aureobasidin A. Journal of Antibiotics (Tokyo)
44, 925–933.
Kim, S. K., Fouts, A. E. and Boothroyd, J. C. (2007).
Toxoplasma gondii dysregulates IFN-gamma-inducible gene expression in human fibroblasts: insights from a genome-wide transcriptional profiling. Journal of Immunology
178, 5154–5165.
Lauer, S. A., Ghori, N. and Haldar, K. (1995). Sphingolipid synthesis as a target for chemotherapy against malaria parasites. Proceeds of the National Academy of Sciences USA
92, 9181–9185.
Meissner, M., Schluter, D. and Soldati, D. (2002). Role of Toxoplasma gondii myosin A in powering parasite gliding and host cell invasion. Science
298, 837–840.
Mina, J. G., Pan, S. Y., Wansadhipathi, N. K., Bruce, C. R., Shams-Eldin, H., Schwarz, R. T., Steel, P. G. and Denny, P. W. (2009). The Trypanosoma brucei sphingolipid synthase, an essential enzyme and drug target. Molecular and Biochemical Parasitology
168, 16–23.
Mina, J. G., Mosely, J. A., Ali, H. Z., Shams-Eldin, H., Schwarz, R. T., Steel, P. G. and Denny, P. W. (2010). A plate-based assay system for analyses and screening of the Leishmania major inositol phosphorylceramide synthase. International Journal of Biochemistry and Cell Biology
42, 1553–1561.
Mina, J. G., Mosely, J. A., Ali, H. Z., Denny, P. W. and Steel, P. G. (2011). Exploring Leishmania major inositol phosphorylceramide synthase (LmjIPCS): insights into the ceramide binding domain. Organic and Biomolecular Chemistry
9, 1823–1830.
Nagiec, M. M., Nagiec, E. E., Baltisberger, J. A., Wells, G. B., Lester, R. L. and Dickson, R. C. (1997). Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. Journal of Biological Chemistry
272, 9809–9817.
Pratt, S., Wansadhipathi-Kannangara, N. K., Bruce, C. R., Mina, J. G., Shams-Eldin, H., Casas, J., Hanada, K., Schwarz, R. T., Sonda, S. and Denny, P. W. (2013). Sphingolipid synthesis and scavenging in the intracellular apicomplexan parasite, Toxoplasma gondii
. Molecular and Biochemical Parasitology
187, 43–51.
Romano, J. D., Sonda, S., Bergbower, E., Smith, M. E. and Coppens, I. (2013).
Toxoplasma gondii salvages sphingolipids from the host Golgi through the rerouting of selected Rab vesicles to the parasitophorous vacuole. Molecular Biology of the Cell
24, 1974–1995.
Salto, M. L., Bertello, L. E., Vieira, M., Docampo, R., Moreno, S. N. and de Lederkremer, R. M. (2003). Formation and remodeling of inositolphosphoceramide during differentiation of Trypanosoma cruzi from trypomastigote to amastigote. Eukaryotic Cell
2, 756–768.
Simons, K. and Ikonen, E. (1997). Functional rafts in cell membranes. Nature
387, 569–572.
Soete, M., Camus, D. and Dubremetz, J. F. (1994). Experimental induction of bradyzoite-specific antigen expression and cyst formation by the RH strain of Toxoplasma gondii in vitro
. Experimental Parasitology
78, 361–370.
Sonda, S., Sala, G., Ghidoni, R., Hemphill, A. and Pieters, J. (2005). Inhibitory effect of Aureobasidin A on Toxoplasma gondii
. Antimicrobial Agents and Chemotherapy
49, 1794–1801.
Takesako, K., Ikai, K., Haruna, F., Endo, M., Shimanaka, K., Sono, E., Nakamura, T., Kato, I. and Yamaguchi, H. (1991). Aureobasidins, new antifungal antibiotics. Taxonomy, fermentation, isolation, and properties. Journal of Antibiotics (Tokyo)
44, 919–924.
Vacaru, A. M., van den Dikkenberg, J., Ternes, P. and Holthuis, J. C. (2013). Ceramide phosphoethanolamine biosynthesis in Drosophila is mediated by a unique ethanolamine phosphotransferase in the Golgi lumen. Journal of Biological Chemistry
288, 11520–11530.
Webster, J. P., Kaushik, M., Bristow, G. C. and McConkey, G. A. (2013).
Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?
Journal of Experimental Biology
216, 99–112.
Welti, R., Mui, E., Sparks, A., Wernimont, S., Isaac, G., Kirisits, M., Roth, M., Roberts, C. W., Botte, C., Marechal, E. and McLeod, R. (2007). Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry
46, 13882–13890.
Wuts, P. G., Simons, L. J., Metzger, B. P., Sterling, R. C., Slightom, J. L. and Elhammer, A. P. (2015). Generation of broad-spectrum antifungal drug candidates from the natural product compound Aureobasidin A. ACS Medical Chemistry Letters
6, 645–649.
Young, S. A., Mina, J. G., Denny, P. W. and Smith, T. K. (2012). Sphingolipid and ceramide homeostasis: potential therapeutic targets. Biochemistry Research International
2012, 248135.
